ATLANTA, GA – – (Businesswire – July 28, 2020) – – Holzer & Holzer, LLC is investigating whether Vaxart, Inc. (“Vaxart” or the “Company”) (NASDAQ: VXRT) complied with federal securities laws. On June 26, 2020, Vaxart issued a news release announcing that it had been selected for Operation Warp Speed, the federal initiative to quickly develop drugs to combat the coronavirus. On July 25, 2020, a New York Times article revealed that Vaxart’s vaccine candidate was included in a trial on primates that a federal agency was organizing in conjunction with Operation Warp Speed. However, according to the report, the Company was not selected to receive significant financial support from Operation Warp Speed. The price of Vaxart’s stock fell following the announcement. If you purchased shares of Vaxart and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at email@example.com or Luke R. Kennedy, Esq. at firstname.lastname@example.org, or by toll-free telephone at (888) 508-6832 to discuss your legal rights.